57808-66-9 Purity
98+%
If you have any other questions or need other size, please get a quote.
Specification
Ambarwati, Yuli, et al. Jurnal Kimia Valensi 3.2 (2017).
This study examined the molecular interaction between chromium(III) nicotinate complexes and human Protein Tyrosine Phosphatase (PTP), a key enzyme target in type 2 diabetes. Using computational docking methods, the study evaluates the potential of chromium nicotinate-a widely used antidiabetic supplement-to act as a regulatory agent through targeted enzyme inhibition.
Two coordination forms of chromium(III) nicotinate were investigated, including O-coordinated trans and cis isomers (trans-[Cr(O-nic)2(OH-)(H2O)3] and cis-[Cr(O-nic)2(OH-)(H2O)3]), and N-coordinated trans isomer: trans-[Cr(N-nic)2(OH-)(H2O)3].
Key Findings
· trans-[Cr(O-nic)2(OH-)(H2O)3] exhibited the strongest binding affinity with an interaction energy of -6.5 kcal/mol. It formed interactions with residues Leu13, Gly14, Cys17, Arg18, Trp49, and Asn50.
· cis-[Cr(O-nic)2(OH-)(H2O)3] showed slightly weaker binding (-6.1 kcal/mol), interacting with Ile16, Trp49, Asn50, Arg53, Asp56, and Tyr131.
· trans-[Cr(N-nic)2(OH-)(H2O)3] also demonstrated significant binding (-6.5 kcal/mol), engaging Leu13, Ser47, Trp49, Asn50, and Tyr131.
· The computational analysis confirmed that hydrogen bonding serves as the primary interaction mechanism between the chromium complexes and PTP. The trans O-coordinated complex formed seven hydrogen bonds and one sulfide bond (2.5 Å distance), indicating stable and specific binding.
Dębski, Bogdan, et al. Probl. Hig. Epidemiol 97 (2016): 95-99.
Chromium(III) is an essential trace element involved in macronutrient metabolism, and its deficiency has been linked to metabolic disorders such as type 2 diabetes. Among dietary supplements, chromium is commonly available as chromium picolinate, chromium nicotinate, or chromium chloride. This case study focused on assessing and comparing the impact of chromium nicotinate and chromium picolinate on apoptosis induction in the HBL-100 human mammary epithelial cells (MECs).
Methods: HBL-100 cells were treated with chromium nicotinate or chromium picolinate at a concentration of 10 μg/L for 1, 3, and 6 hours. Apoptosis was evaluated using laser scanning cytometry (LSC) to quantify subG1 phase cells, and immunofluorescence staining for expression of apoptotic markers (BAX and the 89 kDa fragment of cleaved PARP).
Key Results
· Chromium picolinate significantly induced apoptosis, demonstrated by an increased percentage of cells in subG1 phase, upregulation of BAX expression, and an increase in cleaved PARP.
· Chromium nicotinate did not induce significant apoptosis. Only a slight increase in BAX expression was observed, with no notable changes in subG1 cell population or PARP cleavage.
The molecular formula of Chromium nicotinate is C18H12CrN3O6.
The synonyms for Chromium nicotinate are Chromium(III) nicotinate, 64452-96-6, and chromium(3+);pyridine-3-carboxylate.
The molecular weight of Chromium nicotinate is 418.3 g/mol.
The parent compound of Chromium nicotinate is Nicotinic acid (CID 938).
The component compounds of Chromium nicotinate are Chromium (CID 23976) and Nicotinic acid (CID 938).
Chromium nicotinate was created on October 25, 2006.
Chromium nicotinate was last modified on October 21, 2023.
The IUPAC Name of Chromium nicotinate is chromium(3+);pyridine-3-carboxylate.
The InChIKey of Chromium nicotinate is MSPQQAUTCRWLGR-UHFFFAOYSA-K.
The CAS number of Chromium nicotinate is 64452-96-6.
Download
×